Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597148 | 0.91 | MAPT (0.61) | MAPTGAAKMT2AMEN1GFER | |
| SCHEMBL3529521 | 0.85 | MAPT (0.56) | MAPTGAAKMT2AMEN1GFER | |
| SCHEMBL3529524 | 0.85 | MAPT (0.56) | MAPTGAAKMT2AMEN1GFER | |
| SCHEMBL10787691 | 0.84 | RAB9A (0.55) | MAPTGAAKMT2AMEN1GFER | |
| SCHEMBL5445350 | 0.79 | NPC1 (0.60) | MAPTGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL5522100 | 0.79 | MAPT (0.51) | MAPTGAAKMT2AMEN1GFER | |
| SCHEMBL5402602 | 0.78 | MAPT (0.55) | MAPTGAAKMT2AMEN1GFER | |
| SCHEMBL5402608 | 0.78 | MAPT (0.55) | MAPTGAAKMT2AMEN1GFER | |
| SCHEMBL3372005 | 0.75 | ALDH1A1 (0.57) | MAPTGAAKMT2AALDH1A1POLB | |
| SCHEMBL2094819 | 0.75 | ALDH1A1 (0.61) | MAPTGAAKMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643440-B2 | Peptide PAC1 antagonists | AMGEN INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210395313-A1 | PEPTIDE PAC1 ANTAGONISTS | AMGEN INC. | 2021-12-23 | — | — | US | disclosed |
| EP-3630147-A2 | PEPTIDE PAC1 ANTAGONISTS | Amgen Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018222991-A2 | PEPTIDE PAC1 ANTAGONISTS | AMGEN INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| US-8114606-B2 | Aldo-keto reductase specific immunoglobulin for use in diagnosis, classification and imaging of cell proliferative disorders | THE BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110229909-A1 | RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110195411-A1 | ARL-1 SPECIFIC ANTIBODIES AND USES THEREOF | THE BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (US) | 2011-08-11 | — | — | US | disclosed |
| US-20100056441-A1 | Method for Inhibiting Angiogenesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-03-04 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090269786-A1 | RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2009-10-29 | — | — | US | disclosed |
| US-5861532-A | Solid-phase synthesis of N-alkyl amides | CHIRON CORPORATION (US) | 1999-01-19 | — | — | US | disclosed |
| US-5710244-A | Derivatized calcitonins | UNIVERSITY OF WASHINGTON | 1998-01-20 | — | — | US | disclosed |
| US-5698521-A | INHIBITING BONE RESORPTION | ZYMOGENETICS, INC. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5698672-A | ADMINSTERING TO TREAT OSTEOPOROSIS, PAGET'S DISEASE AND HYPERPARATHYROIDISM | ZYMOGENETICS, INC. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5601992-A | DETECTING INTERACTION BETWEEN PEPTIDE AND TARGET BY PLACING TARGET INTO CONTAINER, OVERLAYING WITH SUBSTRATE, APPLYING BEADS TO SUBSTRATE, EACH BEAD HAVING ASSOCIATED THEREWITH COPIES OF A SINGLE PEPTIDE, ALLOWING DIFFUSION, REACTION | BUNSEN RUSH LABORATORIES, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996031536-A1 | SYNTHETIC CALCITONIN MIMETICS | ZYMOGENETICS, INC. (US) | 1996-10-10 | — | — | WO | disclosed |
| WO-1995018152-A1 | DERIVATIZED CALCITONINS | ZYMOGENETICS, INC. (US) | 1995-07-06 | — | — | WO | disclosed |
| US-5428014-A | Tissue sealants; wound healing agents; medical equipment; biocompatible | ZYMOGENETICS, INC. (US) | 1995-06-27 | — | — | US | disclosed |
| WO-1995005396-A1 | TRANSGLUTAMINASE CROSS-LINKABLE POLYPEPTIDES AND METHODS RELATING THERETO | ZYMOGENETICS, INC. (US) | 1995-02-23 | — | — | WO | disclosed |
| US-5268423-A | Solid phase phenyl ether resin in presence of a Lewis acid acid catalyst | NEW YORK UNIVERSITY (US) | 1993-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | MAPT 4286/4885GAA 1992/4885KMT2A 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.